NAS:ATRA (USA)
Business Description
Atara Biotherapeutics Inc
NAICS : 325412
SIC : 2836
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Compare
Compare
Traded in other countries / regions
AT2.Germany
•
0HIY.UK
•
ATRA.USA
Description
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 17.29 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -6.5 | |||||
| Beneish M-Score | 15.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 12.8 | |||||
| 3-Year EPS without NRI Growth Rate | 11.7 | |||||
| 3-Year FCF Growth Rate | 20.6 | |||||
| 3-Year Book Growth Rate | -25.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.32 | |||||
| 9-Day RSI | 45.88 | |||||
| 14-Day RSI | 41.24 | |||||
| 6-1 Month Momentum % | -44.15 | |||||
| 12-1 Month Momentum % | -32.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | |||||
| Quick Ratio | 3.1 | |||||
| Cash Ratio | 2.97 | |||||
| Days Sales Outstanding | 56.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1453.97 | |||||
| Net Margin % | -1451.79 | |||||
| ROE % | -113.27 | |||||
| ROA % | -76.01 | |||||
| ROIC % | -250.2 | |||||
| ROC (Joel Greenblatt) % | -560.67 | |||||
| ROCE % | -95.47 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 14.26 | |||||
| PB Ratio | 1.47 | |||||
| Price-to-Tangible-Book | 1.88 | |||||
| EV-to-EBIT | -0.13 | |||||
| EV-to-EBITDA | -0.13 | |||||
| EV-to-Revenue | 1.88 | |||||
| EV-to-Forward-Revenue | 1.66 | |||||
| EV-to-FCF | -0.22 | |||||
| Price-to-Net-Current-Asset-Value | 2.99 | |||||
| Price-to-Net-Cash | 3.28 | |||||
| Earnings Yield (Greenblatt) % | -756.62 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:ATRA
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 24.102 | ||
| EPS (TTM) ($) | -3.64 | ||
| Beta | 0.62 | ||
| Volatility % | 100.7 | ||
| 14-Day RSI | 41.24 | ||
| 14-Day ATR ($) | 0.46943 | ||
| 20-Day SMA ($) | 3.6755 | ||
| 12-1 Month Momentum % | -32.75 | ||
| 52-Week Range ($) | 2.83 - 20.04 | ||
| Shares Outstanding (Mil) | 93.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Atara Biotherapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||